Join the hosts as they break down BONESUPPORT Holding AB's Q3 2024 interim report. This episode will cover the company’s impressive 54% sales growth (CER) fueled by the success of CERAMENT® G in the US, as well as their strong earnings performance. The discussion will also cover highlights from the quarter, including the topline results from the SOLARIO study, which demonstrated a potential paradigm shift in the treatment of bone infections.
Podden och tillhörande omslagsbild på den här sidan tillhör
Finna AB. Innehållet i podden är skapat av Finna AB och inte av,
eller tillsammans med, Poddtoppen.
